Takeda has chalked up another milestone for its Alofisel cell therapy for a complication of Crohn's disease, becoming the first allogeneic stem cell therapy to be approved in Japan.
French biopharma company Hybrigenics has made another bid to merge with Belgium's Bone Therapeutics, a specialist in regenerative medicine that is still recovering from a setback in its lea
Roche has largely been a spectator on the side lines as other drugmakers have embraced cell therapies for cancer, but it has made a big play now, pledging $150 million upfront to an allianc
Gilead Sciences' Kite Pharma has mapped out another route to the development of allogeneic or 'off-the-shelf' cell therapies for cancer, using technology developed by Appia Bio, a US startu
NHS England has matched its financial backing of the Cancer Drugs Fund (CDF) with an equivalent pot of money for a new Innovative Medicines Fund (IMF) that will provide early access to cutt
BioNTech has found a use for some of the windfall cash it has raked in from its COVID-19 vaccine, agreeing a deal to buy Kite Pharma's entire neoantigen T cell receptor (TCR) platform for s
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.